Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01673204|
Recruitment Status : Unknown
Verified February 2014 by Yon Su Kim, Seoul National University Hospital.
Recruitment status was: Recruiting
First Posted : August 27, 2012
Last Update Posted : February 13, 2014
Worldwide, the most common cause of chronic kidney disease (CKD) and end stage renal disease (ESRD) is diabetes. Unlike the past, in south korea, diabetes account for more than 40% of ESRD. According to WHO reports in 1998, 100 million people had type 2 diabetes in 1997, and there is expected to increase by 300 million people in 2025. In addition, the expected survival time of patients with diabetes increase compared to previous. In the future, ESRD due to type 2 diabetes is expected to have a significant impact on the health industry. Therefore, prevention of progression to CKD and ESRD in diabetic patients is important to aspect of national health and economic problems. How to stop the progression of diabetic nephropathy is part of modern medicine to be solved.
Strict glycemic control, blood pressure regulation, and use of renin-angiotensin system (RAS) blockers inhibit the development and progression of diabetic nephropathy. Microalbuminuria in diabetic patients has been recognized as a predictor of progression of diabetic nephropathy. Thus, the prevention of elevated urinary albumin excretion is an important therapeutic target for the prevention of renal and cardiovascular events.
In patients with diabetes and hypertension, the drugs that block the RAS are used to treat proteinuria, but still a large number of patients with proteinuria are uncontrolled. In addition, ACE inhibitors or ARB agents actually have a limited effect on reducing the risk of cardiovascular or renal outcome. Also, sulodexide or pentoxyphylline which is reducing proteinuria have some weak evidence in terms of efficacy and safety. Therefore, the introduction of new alternative drugs are required.
Already several study reported that calcitriol or paricalcitol in the renal injury model have renopreventive effect. In addition, in diabetic renal injury mice model reported that vitamin D receptor deficiency leads to glomerulosclerosis. Inhibition of the RAS with combination of paricalcitol and RAS inhibitors effectively prevent renal injury in diabetic nephropathy. Recently, Dick de Zeeuw et al reported that addition of paricalcitol to RAS inhibition safely lower residual albuminuria in patients with diabetic nephropathy. Recent studies reported that elevated concentrations of serum markers of the TNFα and Fas-pathways are strongly associated with decreased renal function in diabetic patients. However, the role of these markers in early progressive renal function decline are not clear. Therefore, the objective of this study is to identify the renoprotective effect as an new treatment of activated vitamin D (Calcitriol) indicating the TNF-α-related anti-inflammatory action and to seek the role as an important biomarker that the changes of TNFR in diabetic nephropathy can predict response to treatment.
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Nephropathy||Drug: Calcitriol Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||276 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Study Start Date :||October 2012|
|Estimated Primary Completion Date :||April 2014|
dosage of 0.5mcg administered orally once daily for 12 month
Placebo Comparator: Placebo
- Changes in renal function with proteinuria [ Time Frame: 12 month after administration ]Comparison of in GFR level from baseline Comparison of proteinuria amount checked by random urine protein/creatinine ratio
- changes in sTNFR and TNF-related proteins [ Time Frame: 12 months after administration ]Comparison of serum TNFR1, TNFR2 levels from baseline
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01673204
|Contact: Sumi Leeemail@example.com|
|Korea, Republic of|
|Seoul National University Hospital||Recruiting|
|Seoul, Korea, Republic of, 110-744|
|Contact: Yonsu Kim, M.D., Ph.D 82-2-2072-2264 firstname.lastname@example.org|
|Contact: Dongki Kim, M.D., Ph.D 82-2-2072-2303 email@example.com|
|Principal Investigator: Yonsu Kim, Ph.D.|
|Sub-Investigator: Dongki Kim, M.D., Ph.D|
|Sub-Investigator: Sumi Lee, M.D.|
|Seoul National University Boramae Medical Center||Not yet recruiting|
|Seoul, Korea, Republic of|
|Contact: Jungpyo Lee, M.D., Ph.D 82-2-870-2261 firstname.lastname@example.org|
|Sub-Investigator: Jungpyo Lee, M.D., Ph.D|
|Study Chair:||Yonsu Kim, M.D., Ph.D||Seoul National University Hospital|